ERBB2 and gastric cancer: Novel anti-HER2 therapeutics (e.g., trastuzumab deruxtecan (T-DXd; DS-8201a) and disitamab vedotin (RC48)) have made significant breakthroughs in the treatment of GC (Nakamura et al. 2021).